Industry News
Pharmaceutical Industry News
The regulatory environment in the…
The regulatory environment in the United States encountered by Moderna during the development of its COVID-19 vaccine bears little resemblance to what the company experienced earlier this week when the FDA refused to review its
It’s déjà vu all over again….
It’s déjà vu all over again. Just as the IgA nephropathy space becomes increasingly crowded, Novartis aims to turn a statistical miss into a regulatory win.
Late Thursday, PTC revealed that…
Late Thursday, PTC revealed that it withdrew its FDA application for Translarna in nonsense mutation Duchenne muscular dystrophy after receiving feedback on its filing from the regulator.
Bayer has cooked up the next phase…
Bayer has cooked up the next phase of its “See Your Risks” campaign with celebrity chef Jeff Mauro. The drugmaker is offering people the chance to dine in Mauro’s immersive dark dining experience, the Heart
Senate Questions Health Care Firm for Profiting Off Program Meant for Poor
The program was meant to help hospitals provide for poor patients by offering drug savings. But critics say a Texas company has turned it into a big business, driving up costs for patients and insurers.
Eli Lilly and Innovent Biologics…
Eli Lilly and Innovent Biologics have deepened their ties with a new type of deal. China has indicted AstraZeneca and its former top exec in the country following investigations that emerged in 2024. Madrigal has
Novo plans to invest in an…
Novo plans to invest in an expansion of its facility in Athlone, Ireland, to produce its Wegovy pill for markets beyond the U.S., the company’s CEO, Mike Doustdar, told Bloomberg News in a newly published
The company claims Botox should be…
The company claims Botox should be excluded from Inflation Reduction Act (IRA) pricing negotiations due to its status as a plasma-derived drug, which is meant to be excluded from IRA negotiations.
Alnylam achieved profitability for…
Alnylam achieved profitability for the first time in its history in 2025. But disappointing sales performance from Amvuttra in the closely watched ATTR-CM market and some expected turbulence in 2026 are weighing on its shares.
Supreme Group has added Broth to…
Supreme Group has added Broth to the mix of ad agencies it has cooked up in recent years. Backed by a private equity firm, Supreme has bought companies in quick succession to strengthen its marketing
One day after CSL revealed that it…
One day after CSL revealed that it had suddenly replaced its CEO, the company provided dismal financial figures that helped explain why it is undergoing the leadership change. In its half-year report, CSL said that
Belén Garijo’s appointment…
Belén Garijo’s appointment restores a woman CEO to the ranks of the top 10 Big Pharma companies.
U.S. Health Officials Defend Rejection of Moderna’s Flu Vaccine
The F.D.A.’s refusal to examine the company’s mRNA shot drew widespread criticism from doctors and was divisive within the agency.
OpenAI’s Biggest Challenge Is Turning Its A.I. Into a Cash Machine
The maker of ChatGPT hopes to triple its revenue in the coming year because it is planning to spend tens of billions of dollars. The clock is ticking.
For months now, all signs have…
For months now, all signs have pointed to a looming, steep dropoff in pharmas’ spending on traditional TV advertising. One brand that seems not to have gotten the memo, however, is Johnson & Johnson’s Tremfya.
Following a more than decade-long…
Following a more than decade-long legal back-and-forth over the generic drug carveout practice known as “skinny” labeling, GSK and Teva have put their dispute to bed, new court documents show.
Chinese prosecutors have brought…
Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs.
Gilead is expecting newly launched…
Gilead is expecting newly launched HIV PrEP Yeztugo to bring in $800 million in 2026 sales, a figure Mizuho Securities analysts described as "probably" conservative.
For all its success across a wide…
For all its success across a wide range of cancer types, Merck’s superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer. But now, 13 years
Acabo de regresar de China. Estados Unidos no está ganando
Si Estados Unidos quiere ser competitivo frente a China, tiene que poner orden en su economía.